Zacks Investment Research lowered shares of Histogenics Corporation (NASDAQ:HSGX) from a buy rating to a hold rating in a report released on Saturday morning.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
HSGX has been the topic of a number of other research reports. HC Wainwright set a $4.00 target price on shares of Histogenics Corporation and gave the stock a buy rating in a research note on Saturday, May 13th. Canaccord Genuity restated a buy rating and set a $4.00 target price on shares of Histogenics Corporation in a research note on Friday, August 11th. Finally, ValuEngine upgraded shares of Histogenics Corporation from a strong sell rating to a sell rating in a research note on Friday, June 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Histogenics Corporation currently has a consensus rating of Hold and a consensus price target of $5.25.
Shares of Histogenics Corporation (NASDAQ:HSGX) opened at 2.0378 on Friday. The firm has a 50-day moving average of $1.83 and a 200 day moving average of $1.75. The company’s market cap is $45.83 million. Histogenics Corporation has a 12 month low of $1.45 and a 12 month high of $3.64.
Histogenics Corporation (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. During the same quarter in the previous year, the company posted ($0.61) earnings per share. On average, analysts expect that Histogenics Corporation will post ($1.09) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2887489/histogenics-corporation-hsgx-downgraded-by-zacks-investment-research-to-hold.html.
An institutional investor recently raised its position in Histogenics Corporation stock. Sabby Management LLC boosted its position in shares of Histogenics Corporation (NASDAQ:HSGX) by 15.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,095,422 shares of the biotechnology company’s stock after acquiring an additional 150,531 shares during the period. Sabby Management LLC owned 5.31% of Histogenics Corporation worth $1,895,000 at the end of the most recent quarter. 50.08% of the stock is owned by institutional investors.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.